Shay Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Shay Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,662	Closed	-$24.9K	–	663
2026 Q1	$24.9K	Hold	10,662	–	–	﹤0.01%	464
2025 Q4	$14.4K	Buy	+10,662	New	+$15.5K	﹤0.01%	475

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Shay Capital's ZNTL Position: Q2 2026 in Review

Shay Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 10,662 shares — an estimated $24.9K sold.

Shay Capital first reported a position in ZNTL in Q4 2025 and held it in 2 quarters. The position peaked at $24.9K in Q1 2026. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Shay Capital reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 10,662 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $24.9K.
Shay Capital first reported a position in Zentalis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Shay Capital's Zentalis Pharmaceuticals position peaked at $24.9K in Q1 2026.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.